Stay updated on Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial page.

Latest updates to the Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial page
- Check6 days agoChange DetectedAdded 'Multiple myeloma' as a page topic and included a related topic link to MedlinePlus Genetics; updated the page revision from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedDeleted the disease term 'Multiple Myeloma' from the page and removed the Related Topic 'MedlinePlus Genetics'. This could reduce clarity about the study's focus and remove an external educational resource, while most other study content remains unchanged.SummaryDifference0.1%

- Check35 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check57 days agoChange DetectedAdded related-topic links for 'Multiple myeloma' and 'MedlinePlus Genetics' on the Study Details page to provide quick access to background information. No changes to study data or user workflows were made.SummaryDifference0.1%

- Check64 days agoChange DetectedRemoved related topics 'Multiple Myeloma' and 'MedlinePlus Genetics' from the page's related topics.SummaryDifference0.1%

Stay in the know with updates to Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial page.